Image

LucenceINSIGHT™ is a multi-cancer early detection (MCED) next generation sequencing test that screens for the signal of up to 50 cancers in one simple blood draw.

The test uses Lucence’s amplicon-based mirror barcoding technology to detect circulating tumor and viral DNA. It then predicts tumor location with machine learning.

Image
Image

LucenceINSIGHT™ Screens For Cancer With High Accuracy.

Image
Image

Evidence

  • LucenceINSIGHT™ reported 100% positive predictive value (PPV) from a prospective real-world cohort of 264 asymptomatic individuals in 2023.3
  • A performance of 81% sensitivity and 99% specificity was reported from a retrospective cohort of 601 patient samples in 2024.1
Image

Case Study: Colorectal Cancer3

  • Patient: 60+ year old asymptomatic Southeast Asian male
  • Detected mutation: RHOA G62E at 0.4% VAF
  • Diagnostic workup: PET-CT
  • Final Diagnosis: Stage III colorectal cancer
Image

Focal uptake detected in right ascending colon

  • Patient: 60+ year old asymptomatic Southeast Asian male
  • Detected mutation: RHOA G62E at 0.4% VAF
  • Diagnostic workup: PET-CT
  • Final Diagnosis: Stage III colorectal cancer

Focal uptake detected in right ascending colon

See which LucenceINSIGHT™ plan is right for your patients

Frequently Asked Questions

Image

References

  1. Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042.
  2. Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212–222.
  3. Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626.
Image
SINGAPORE OFFICE

211 Henderson Rd #04-02
Henderson Industrial Park
Singapore 159552

sales.asean@lucence.com
+65 6592 5102

HONG KONG OFFICE

Suite 1018, Unit 1001, 10/F, Mira Place Tower A
132 Nathan Road
Tsim Sha Tsui, Kowloon, Hong Kong

sales.hk@lucence.com
+852 5182 7199

FOLLOW US

©2024 Lucence Diagnostics Pte Ltd. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners. The information on this site is intended for audiences in Singapore and Hong Kong only.